Nektar rises 11% as BTIG initiates buy rating on autoimmune

Nektar Rises 11% As BTIG Initiates Buy Rating On Autoimmune

2 weeks from now

BTIG has initiated Nektar Therapeutics (NASDAQ:NKTR) with a buy rating, citing the potential of rezpegaldesleukin, a potential first-in-class regulatory T cell stimulator, for autoimmune …

msn.com

Nektar Rises 11% As BTIG Initiates Buy Rating On - One News Page

2 weeks from now

Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset • • Markets • One News Page: Monday, 30 September 2024

onenewspage.com

BTIG Upgrades Nektar Stock, Sees Upside On Rezpeg Potential

2 weeks from now

Sep 30, 2024  · BTIG has initiated coverage on shares of Nektar Therapeutics (NASDAQ: NASDAQ: NKTR) with a Buy rating and a price target set at $4.00.. The firm identified a …

investing.com

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded By

2 weeks from now

Jan 9, 2025  · Finally, BTIG Research reissued a "buy" rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Three …

marketbeat.com

Nektar Therapeutics (NKTR) Latest Stock News - Seeking Alpha

2 weeks from now

Dec 27, 2024  · Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset SA News Mon, Sep. 30 3 Comments Nektar Therapeutics Non-GAAP EPS of -$0.19, revenue of …

seekingalpha.com

Nektar Assumed With A Buy At BTIG - TipRanks.com

2 weeks from now

BTIG assumed coverage of Nektar with a Buy rating and $4 price target.There is a compelling disconnect between rezpegaldesleukin’s broad potential in I&I – Immunology & Inflammation – …

tipranks.com

BTIG Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, …

2 weeks from now

BTIGanalyst Julian Harrison initiates coverage on $Nektar Therapeutics(NKTR.US)$ with a buy rating, and sets the target price at $4.According to TipRanks data, the ...

futunn.com

Recent News For $NKTR | Nektar Therapeutics - SwingTradeBot

2 weeks from now

Aug 9, 2024  · Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset: Sep 25: Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV …

swingtradebot.com

Eczema Drug Developer Nektar Gains Analyst Confidence With …

2 weeks from now

Nov 4, 2024  · Piper initiates with an Overweight rating and a price target of $7, an upside of over 400%. Price Action: NKTR stock is up 10.2% at $1.355 at last check Monday. Read Next:

yahoo.com

B. Riley Securities Initiates Coverage On Nektar Therapeutics With …

2 weeks from now

Jan 8, 2025  · B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

sahmcapital.com

B. Riley Begins Coverage On Nektar Therapeutics (NASDAQ:NKTR)

2 weeks from now

6 days ago  · Nektar Therapeutics has a one year low of $0.48 and a one year high of $1.93. The firm has a market cap of $210.28 million, a PE ratio of -1.36 and a beta of 0.59. Insiders Place …

etfdailynews.com

BTIG Assumes Nektar Therapeutics (NKTR) At Buy

2 weeks from now

Sep 30, 2024  · BTIG analyst Julian Harrison assumes coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $4.00.The analyst comments "We …

streetinsider.com

BTIG - Recent News & Activity - Crunchbase

2 weeks from now

Oct 21, 2024  · SeekingAlpha — Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset . ... News • Sep 11, 2024. SeekingAlpha — VP Harris’s small business tax …

crunchbase.com

BTIG Lifts Upstart Stock Rating To Neutral From Sell, Removes $14 PT

2 weeks from now

Nov 11, 2024  · The company witnessed a 43% sequential increase in lending volume and a significant rise in revenue, including a 28% increase in fee revenue to $168 million. The loan …

investing.com